Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 14, 2005. The report details corporate actions regarding share repurchases and updates on directors' interests in company shares and employee benefit plans.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes and share ownership details.
- Share Repurchases: The Company purchased a total of 2,765,000 Ordinary shares on March 9, 10, and 11, 2005.
- Repurchase Prices: Prices ranged from 1,260.68 pence to 1,269.17 pence per share.
- Treasury Shares: Following the March 11 transaction, the Company held 79,823,000 shares in Treasury.
- Shares in Issue: Excluding Treasury shares, 5,863,261,233 shares were in issue as of March 11, 2005.
Material Changes
The primary material change reported is the reduction of outstanding shares through the Company's share buyback program authorized at the Annual General Meeting on May 17, 2004. Additionally, there were minor adjustments in the number of American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan due to fund movements.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of share transactions and director interest changes.
Investor Verification Checklist
- Verify the total cost of the 2,765,000 shares repurchased between March 9 and March 11, 2005.
- Confirm the updated total number of shares in issue (5,863,261,233) and Treasury shares (79,823,000) as of March 11, 2005.
- Review the specific impact of the US Retirement Savings Plan ADR movement on director interests for Dr. J.P. Garnier and Dr. T. Yamada.
- Note that this filing does not contain operational or financial performance data for the period.